June 2011 :: Antitrust Lawyer Blog
Squeezed On: June 9, 2011

Local Price Cutting Keeps Merger Case in DC

On June 6, 2011, the US District Court for the District of Columbia denied defendant H&R Block’s motion to transfer venue. The district court ruled that H&R Block failed to meet their burden to show that a transfer of this case to the Western District of Missouri is warranted in the interests of justice.

Continue reading " Local Price Cutting Keeps Merger Case in DC " »

Squeezed On: June 2, 2011

Accountable Care Organizations: Dilemma or Opportunity

The Affordable Care Act of 2010 encourages health care providers to form integrated organizations to jointly offer services in order to reduce costs and improve the quality of health care in the United States. Section 3022 of the Act provides for the formation of Accountable Care Organizations (“ACOs”) to serve fee-for-service Medicare beneficiaries through Medicare’s Shared Savings Program (“SSP”). ACOs must sign up with the Department of Health and Human Services’ Centers for Medicare and Medicaid Services (“CMS”) to participate in the program for at least three years.

Continue reading " Accountable Care Organizations: Dilemma or Opportunity " »

Squeezed On: June 1, 2011

FTC Settlement Requires Grifols to Divest Assets in the Plasma-Derived Drug Industry

On June 1, 2011, the Federal Trade Commission (“FTC”) entered into a consent agreement with Grifols, S.A. (“Grifols”), a Spain based manufacturer of plasma-derived drugs requiring Grifols to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. The antitrust review took approximately a year as the deal was announced on June 6, 2010. The transaction was worth approximately $3.4 billion. The settlement resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws.

Continue reading " FTC Settlement Requires Grifols to Divest Assets in the Plasma-Derived Drug Industry " »